The $195 Million Voucher: How Denali Turned a Hunter Syndrome Approval Into a Pipeline War Chest
Denali's $195M PRV sale after AVLAYAH's March 2026 FDA approval reveals how rare disease wins now fund the next...
Priority Review Voucher
Fortress Biotech’s $205M Voucher Sale Is the Smartest Capital Move No One Is Talking About
Fortress Biotech just converted a rare pediatric disease priority review voucher into $205 million in cash — while the...